IRLAB Therapeutics AB (publ) Working Capital to Net Assets Ratio
IRLAB Therapeutics AB (publ) working capital to net assets ratio. IRLAB Therapeutics AB (publ) (IRLAB-A) has a Working Capital to Net Assets ratio of -70.4% as of December 2025. Working capital of Skr-21.62 Million (current assets of Skr85.87 Million minus current liabilities of Skr107.49 Million) is measured against net assets of Skr30.72 Million. A higher ratio indicates strong short-term liquidity financed by the equity base. Check IRLAB-A tangible net assets ratio to evaluate the tangible quality of the company's equity base.
WC/NA Ratio
Working Capital
Current Assets
Current Liabilities
Working Capital to Net Assets Ratio of IRLAB Therapeutics AB (publ) (2014–2025)
Working capital to net assets ratio of IRLAB Therapeutics AB (publ) from 2014 to 2025. This chart shows how IRLAB Therapeutics AB (publ)'s Working Capital to Net Assets ratio has evolved across 12 annual periods from 2014 to 2025. As of December 2025, the ratio stands at -70.4%, reflecting working capital of Skr-21.62 Million against net assets of Skr30.72 Million SEK. See IRLAB Therapeutics AB (publ) defensive interval ratio to measure how many days the company can operate on defensive assets alone.
IRLAB Therapeutics AB (publ) Working Capital to Net Assets Ratio by Year (2014–2025)
IRLAB Therapeutics AB (publ) working capital to net assets ratio by year from 2014 to 2025. The table below presents the year-by-year Working Capital to Net Assets ratio for IRLAB Therapeutics AB (publ) from 2014 to 2025, covering 12 annual filings. Each row shows current assets, current liabilities, working capital, net assets, the ratio, and the change in percentage points compared to the prior year. For the complete balance sheet picture, see IRLAB-A asset base.
| Year | WC/NA Ratio | Working Capital (SEK) | Net Assets | Current Assets | Current Liabilities | Change (pp) |
|---|---|---|---|---|---|---|
| 2025 | -70.4% | Skr-21.62 Million | Skr30.72 Million | Skr85.87 Million | Skr107.49 Million | ▼ -7.6 pp |
| 2024 | -62.8% | Skr-20.48 Million | Skr32.63 Million | Skr79.56 Million | Skr100.04 Million | ▼ -137.8 pp |
| 2023 | 75.0% | Skr86.86 Million | Skr115.76 Million | Skr123.59 Million | Skr36.73 Million | ▼ -6.2 pp |
| 2022 | 81.3% | Skr236.34 Million | Skr290.83 Million | Skr268.68 Million | Skr32.34 Million | ▼ -6.9 pp |
| 2021 | 88.1% | Skr352.04 Million | Skr399.48 Million | Skr421.44 Million | Skr69.40 Million | ▲ +12.6 pp |
| 2020 | 75.5% | Skr262.82 Million | Skr347.88 Million | Skr283.74 Million | Skr20.92 Million | ▲ +22.5 pp |
| 2019 | 53.1% | Skr96.54 Million | Skr181.83 Million | Skr119.88 Million | Skr23.34 Million | ▼ -7.2 pp |
| 2018 | 60.2% | Skr128.01 Million | Skr212.48 Million | Skr140.47 Million | Skr12.46 Million | ▲ +14.9 pp |
| 2017 | 45.3% | Skr70.25 Million | Skr155.00 Million | Skr78.22 Million | Skr7.97 Million | ▲ +26.7 pp |
| 2016 | 18.6% | Skr19.37 Million | Skr103.89 Million | Skr28.19 Million | Skr8.82 Million | ▲ +6.9 pp |
| 2015 | 11.7% | Skr10.79 Million | Skr92.03 Million | Skr16.07 Million | Skr5.28 Million | ▼ -6.1 pp |
| 2014 | 17.8% | Skr15.77 Million | Skr88.57 Million | Skr21.11 Million | Skr5.34 Million | — |